

WEDNESDAY, 12th DECEMBER 2012 COMMENCING 10.30 AM (UNTIL 4.00 PM APPROX)

AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

		Enclosure
1.	Welcome and introduction	
2.	Apologies	
3.	Declarations of interest	
4.	Chairman's report (verbal update)	
5.	Minutes of previous meeting	1/AWMSG/1212
6.	Appraisal 1: Full Submission Argatroban (Exembol®) for anticoagulation in adult patients with heparin-induced thrombocytopaenia type II who require parentral antithrombotic therapy	2 /AWMSG/1212 Appendices
7.	Appraisal 2: Full Submission Eplerenone (Inspra [®]) in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF≤30%)	3/AWMSG/1212 Appendices
8.	Appraisal 3: Limited Submission Sildenafil citrate (Revatio®) for the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease	4 /AWMSG/1212 Appendices
9.	Appraisal 4: Limited Submission Bortezomib (Velcade®) for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation	5 /AWMSG/1212 Appendices
10	AWPAG Update (draft minutes – October 2012)	6 /AWMSG/1212
11.	National Prescribing Indicators 2013 – 2014	7 /AWMSG/1212
12.	Date of next meeting:	

Wednesday, 6th February 2013 at Cardiff Metropolitan University